Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus

NCT07563699 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabete Type 2

Interventions

DRUG: SG Depot 2 mg
DRUG: SG Depot 4 mg
DRUG: SG Depot 6 mg
DRUG: SG Depot 8 mg

Sponsor

Mapi Pharma Ltd.